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Successful hematopoietic stem cell transplantation (HSCT), 
both  autologous  and  allogeneic,  requires  a  rapid  and  durable 
engraftment, with neutrophil (>500/μL) and platelet (>20,000/
μL) reconstitution. Factors influencing engraftment after autolo-
gous or allogeneic HSCT were investigated in 65 patients: 25 
autologous peripheral stem cell transplantation (PBSCT) and 40 
allogeneic  bone  marrow  transplantation  (BMT)  patients.  The 
major factor affecting engraftment was the graft source for HSCT. 
Neutrophil and platelet recovery were more rapid in autologous 
PBSCT than in allogeneic BMT [neutrophil occurring in median 
on day 10.00 (09.00/11.00) and 19.00 (16.00/23.00) and platelet 
on day 11.00 (10.00/13.00) and 21.00 (18.00/25.00), respec-
tively; p < 0.0001]. The type of disease also affected engraftment, 
where multiple myeloma (MM) and lymphoma showed faster 
engraftment when compared with leukemia, syndrome myelodys-
plastic (SMD) and aplastic anemia (AA) and MM presented the 
best overall survival (OS) in a period of 12 months. Other factors 
included the drug used in the conditioning regimen (CR), where 
CBV, melphalan (M-200) and FluCy showed faster engraftment 
and M-200 presented the best OS, in a period of 12 months and 
age, where 50–59 years demonstrated faster engraftment. Sex did 
not influence neutrophil and platelet recovery.
Introduction
Hematopoietic  stem  cell  transplantation  (HSCT)  is  a  widely 
accepted  therapeutic  modality  for  a  number  of  malignant, 
  hematologic,  immunologic  and  genetic  diseases.1  This  therapy 
consists  of  the  intravenous  infusion  of  hematopoietic  progenitor 
cells to reestablish marrow function in patients with damaged or 
defective bone marrow. Allogeneic HSCT involves the transfer of 
marrow from a donor to another person. It has been preferentially 
performed in patients with under 60 years of age, because of a higher 
incidence of graft-versus-host disease in older patients. Autologous 
HSCT involves the use of the patient’s own marrow to reestablish 
hematopoietic cell function after the administration of high-dose 
chemotherapy and can be safely performed in older patients, because 
there is no risk of graft-versus-host disease as a complication.2
Autologous  transplantation  has  been  performed  particularly 
in patients with multiple myeloma or lymphoma3,4 whereas allo-
geneic transplantation is preferred for patients with leukemias or 
myeloproliferative diseases.5
Graft failure or graft rejection after HSCT remains a severe 
complication  and  may  be  manifested  as  either  lack  of  initial 
engraftment  of  donor  cells,  or  loss  of  donor  cells  after  initial 
engraftment.  Rejection  is  a  major  cause  of  graft  failure.  Other 
possible causes include viral infections, drug toxicity and septi-
cemia. The use of granulocyte-colony-stimulating factor (G-CSF) 
mobilized  peripheral  blood  stem  cell  transplantation  (PBSCT) 
instead of bone marrow, may reduce the rates of graft rejection,6 
enhanced engraftment and accelerated hematopoietic recovery7-9 
because PBSCT affords about 10-fold more T cells,10,11 compared 
to bone marrow, and a 2-fold higher CD34+ cell dose. However, 
most studies have reported a higher risk of chronic graft-versus-
host disease (GVHD) with allogeneic PBSCTs.12,13 In autologous 
HSCT,  the  major  problem  is  that  malignant  cells,  with  their 
inherent  resistance  to  chemotherapy,  might  survive  and  their 
reinfusion probably contributes to the high incidence of relapse 
observed after this therapy.14
Administration  of  high  doses  of  chemotherapy  (including 
busulfan, cyclophosphamide and or etoposide), with or without 
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total body irradiation (TBI), is a feature of HSCT protocols, for 
malignant  and  non-malignant  diseases.15  These  myeloablative 
CRs can be more or less toxic, depending on the drug utilized. 
In addition, the speed and durability of engraftment are impor-
tant for successful HSCT with both neutrophil (>500/μL) and 
platelet (>20,000/μL) reconstitution. It is important to improve 
our knowledge about the different factors affecting hematopoetic 
recovery after HSCT to further enhance the safety of this proce-
dure. The objective of this study is to identify predictive factors 
affecting a rapid engraftment in patients undergoing autologous 
and allogeneic HSCT.
Results
In 65 (100%) patients examined, 3 (04.62%) did not present 
engraftment and in 62 (93.94%) neutrophil and platelet engraft-
ment occurred.
Kruskal-Wallis  ANOVA  followed  by  Mann-Whitney  U  test 
demonstrated that in terms of neutrophil and platelet engraftment 
there was no significant difference between the sexes. The Fisher 
test also showed no difference between the sexes in terms of OS in 
the periods of <6 months and 6–12 months (Table 2).
There were statistically significant differences in neutrophil and 
platelet engraftment between patients <20 years old (neutrophil) 
and 20–29 years old (platelet) from 50–59 years old, where neutro-
phil  engraftment  occurred  more  rapidly  in  the  50–59  year-old 
group, occurring in median on day 11.00 (10.00/18.00) and 19.00 
(16.00/29.00), respectively and platelet engraftment in median on 
day  13.00  (10.00/21.00)  and  22.00  (13.00/25.00),  respectively   
(p < 0.005), (Table 3).
The  effect  of  disease  type  on  engraftment  was  investigated. 
Neutrophil  and  platelet  engraftment  occurred  more  rapidly  in 
MM  than  in  leukemias,  SMD  and  AA,  neutrophil  engraft-
ment  occurring  in  median  on  day  11.00  (10.00/11.50),  18.00 
(16.00/20.00)  (p  <  0.0001),  20.50  (18.50/25.50)  and  22.00 
(18.00/29.00) (p < 0.005), respectively and platelet engraftment in 
median on day 11.00 (10.00/13.00), 21.00 (17.00/25.00), 23.00 
(21.00/26.50) and 24.00 (20.00/29.00), respectively (p < 0.005); 
Neutrophil  and  platelet  engraftment  occurred  more  rapidly  for 
lymphomas than for leukemias, SMD and AA, neutrophil engraft-
ment occurring on day 10.00 (09.00/15.50), 18.00 (16.00/20.00), 
20.50 (18.50/25.50) and 22.00 (18.00/29.00), respectively and 
platelet engraftment occurring on day 13.00 (10.50/16.00), 21.00 
(17.00/25.00),  23.00  (21.00/26.50)  and  24.00  (20.00/29.00), 
respectively (p < 0.005). OS presented a statistically significant 
difference between MM and SMD at 6–12 months, being 100% 
and  62.5%,  respectively  (p  <  0.05),  (Table  4).  No  significant 
differences where shown for engraftment time or for OS among 
the different types of leukemias or among the different types of 
lymphomas (data not shown).
Neutrophil and platelet engraftment occurred more rapidly in 
autologous PBSCT than in allogeneic BMT. Neutrophil engraft-
ment occurred in median on day 10.00 (09.00/11.00) and 19.00 
(16.00/23.00), respectively and platelet engraftment occurred in 
median  on  day  11.00  (10.00/13.00)  and  21.00  (18.00/25.00), 
respectively (p < 0.0001), (Table 5).
In  relation  to  the  effect  of  CR  on  engraftment,  neutrophil 
and  platelet  engraftment  occurred  more  rapidly  in  patients 
that used CBV, when compared to those using FluCy, CyTBI, 
BuCy120, BuCy200 and Cy200, neutrophil engraftment occur-
ring in median on day 09.00 (09.00/10.50), 12.50 (11.50/16.00), 
20.00 (17.50/21.00), 19.00 (18.00/23.00), 23.50 (22.00/25.00) 
and  19.00  (18.00/29.00)  (p  <  0.05),  respectively;  and  neutro-
phil engraftment was more rapid in patients using M-200 when 
compared to those using CyTBI, BuCy120, BuCy200 and Cy200 
and FluCy than BuCy120 (p < 0.05), occurring in median on day 
11.00 (10.00/11.50) for M-200. Platelet engraftment occurred in 
median on day 11.50 (10.00/13.00) for CBV, 15.50 (13.50/17.50) 
for FluCy, 20.00 (18.00/22.00) for CyTBI, 22.00 (21.00/25.00) 
for BuCy120 and 25.00 (24.00/26.00) for BuCy200; was more 
rapid in patients that used M-200 in comparison to those using 
FluCy, CyTBI, BuCy120 and BuCy200, occurring in median on 
day 11.00 (10.00/13.00) for M-200; more rapid in FluCy than 
in BuCy120, (p < 0.05). OS was significantly different between 
M-200 with CyTBI and BuCY200 in the period of 6–12 months, 
being 100%, 50% and 33.33% respectively (p < 0.05), (Table 6).
Discussion
Mobilized peripheral blood stem-cell transplantation (PBSCT) 
has largely replaced the use of bone marrow as the preferred source 
of  hematopoietic  stem-cell  in  autologous  transplant16  and  has 
been increasingly used in the allogeneic procedure.17 PBSCT is 
better than BMT with regard to hospitalization period, transplant-
related mortality and main produces a more rapid hematopoietic 
reconstitution9,13,17  than  that  using  marrow  derived  stem-cells, 
probably because of the higher content of committed hematopoi-
etic  precursor  cells.10,11,14  In  line  with  this,  we  and  other 
authors9,12,13,18,19 found a more rapid hematologic recovery, with 
a shorter interval of time for neutrophil and platelet engraftment 
with  PBSCT  when  compared  with  BMT. This  finding  in  our 
case specific can be due that the PBSCT enhance engraftment 
and accelerate hematopoietic recovery7,8,9,13 and all patients with 
PBSCT realized autologous transplantation that is a more simple 
proceeding when compared with BMT, because involves the use 
of  the  patient’s  own  marrow  to  reestablish  hematopoietic  cell 
function.2
Allogeneic HSCT has been preferentially performed in patients 
under the age of 60 years, being that 40–50 is considered old for 
this  procedure,  because  of  a  higher  incidence  of  complications 
in the older patients. On the other hand, autologous HSCT can 
be performed safely in older patients, because it is a more simple 
procedure  and  presents  fewer  complications.2  In  terms  of  the 
effect of age on neutrophil and platelet engraftment, we found 
that engraftment was more rapid in the 50–59 year-old group. 
This finding could be due to the fact that the older group was 
also linked with some more favorable variables. For example, most 
of the patients in the older group underwent the more favorable 
autologous PBSCT (Table 3) and received M-200 and CBV, which 
were also associated with a faster engraftment.
In relation to the effect of disease type on engraftment, neutro-
phil and platelet engraftment occurred more rapidly in MM and in 
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lymphomas when compared with leukemias, SMD and AA. This 
may also be due to association with other more favorable factors, 
i.e., patients with MM and Hodgkin or no-Hodgkin lymphoma, 
mainly  underwent  autologous  PBSCT,  with  M-200  and  CBV, 
which showed more rapid engraftment than the allogeneic HSCT 
with other drugs utilized in the CRs for leukemias, SMD and 
AA patients. The same occurred in OS, where patients with MM 
showed a better OS than that for SMD, probably because of its 
association with variables such as autologous PBSCT, and the use 
of M-200. Carral et al.20 showed that the leukemia group had a 
delayed hematopoietic recovery when compared with MM and 
lymphomas and suggested that residual leukemia in the patient 
may also contribute to delayed engraftment.
The  objective  of  clinical  research  is  to  find  chemotherapy 
drugs that produces minimal toxic effects on normal tissue. Today, 
chemotherapy is performed with a combination of drugs, because 
it allows maximal cellular death with tolerable toxic limits and 
avoids cell resistance.21 In this study, it can be observed that CBV, 
M-200 and FluCy produced better engraftment than the other CRs 
with high doses of cyclophosphamide or the presence of busulfan 
cytostatic drugs. The OS was also better in M-200 patients than 
in those using other drugs such as CyTBI and BuCy200, probably 
because of Cy and TBI toxicity. In the case of FluCy, Srinivasan 
et al.22 demonstrated that fludarabine associated to cyclophosph-
amide helped achieve engraftment, allowing a reduction of the 
traditionally high dose of cyclophosphamide. The same authors 
indicated that fludarabine increased engraftment rates, and showed 
minimal morbidity.23-26 George et al.27 observed that fludarabine 
improved OS in children with AA.
In summary, our study shows that the most important variable 
influencing engraftment in patients undergoing HSCT was the 
source, being that autologous PBSCT resulted in faster neutrophil 
and platelet engraftment. Another important variable was the CR, 
where CBV, M-200 and FluCy produced faster neutrophil and 
platelet engraftment. Other variables such as disease type and age 
that showed an influence were probably associated with the source 
and CR utilized in HSCT.
Materials and Methods
Patients. This is a retrospective study, where 25 patients who 
were undergoing autologous HSCT and 40 undergoing allogeneic 
HSCT, in the onco-hematology unit of the Hospital Universitario 
of  the  Universidade  Federal  de  Santa  Maria,  Brazil,  between 
January 2006 and December 2007, were investigated. The infor-
mation about factors affecting the engraftment in HSCT patients 
were taken from patient files.
The  present  study  was  approved  by  the  Human  Ethical 
Committee of the Universidade Federal de Santa Maria, protocol 
number: 0152.0.243.000-06.
Table 1 shows the pre-transplant characteristics, graft source 
and the conditioning regimens of patients undergoing autologous 
and allogeneic HSCT.
Conditioning regimens. The patients were divided in condi-
tioning regimen groups according to diseases and HSCT sources. 
M-200: melphalan (200 mg/m2) given only for 1 day (day minus 
Table 1  Pretransplantation characteristics of patients
  Number of patients 
  (n = 65)
Median age (years)  39.23 ± 15.13
Sex
  Male  38
  Female  27
Diagnosis
  Multiple myeloma  12
  Lymphoma
    Hodgkin  10
    No Hodgkin  11
  Leukemia
    Acute myeloid  08
    Chronic myeloid  06
    Acute lymphoblastic  02
  Myelodysplasia  08
  Aplastic anemia  08
Graft source
  Allogeneic BMT  40
  Autologous PBSCT  25
Conditioning regimen
  BuCy 120  19
  BuCy 200  03
  Cy 200  05
  M-200  12
  CBV  13
  FluCy  04
  BEAM  05
  CyTBI  04
BMT, bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; BuCy120, 
busulfan + cyclophosphamide 120 mg; BuCy200, busulfan + cyclophosphamide 200 mg; Cy200, 
cyclophosphamide 200 mg; M-200, melphalan 200 mg; CBV, cyclophosphamide + carmustine + 
etoposide; FluCy, fludarabine + cyclophosphamide; BEAM, carmustine + etoposide + arabynoside 
+ melphalan; CyTBI, cyclophosphamide + total body irradiation.
Table 2  Influence of sex on engraftment
  Male  Female 
  (n = 38)  (n = 27)
No engraftment  01  02
Engraftment  37  25
Neutrophil engraftment (day)  13.00  16.00 
  (10.00/19.00)  (11.00/19.00)
Platelet engraftment (day)  16.00  20.00 
  (12.00/21.00)  (13.00/23.00)
OS (<6 months)  36/38 (94.74%)  23/27 (85.18%)
OS (6–12 months)  31/38 (81.58%)  21/27 (77.78%)
OS: overall survival; Neutrophil and platelet engraftment were expressed as median (lower/upper 
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transplantation (days minus 8 to minus 5) +   cyclophosphamide 
(60 mg/m2), given for 2 consecutive days, starting 4 days before 
the  transplantation  (days  minus  4  to  minus  3)  for  acute  and 
3)  before  the  transplantation  for  multiple  myeloma  in  PBSCT. 
CBV: cyclophosphamide (1,500 mg/m2) given for 4 consecutive 
days starting 6 days before the transplantation (days minus 6 to 
  minus  3)  +  carmustine  (BCNU—450  mg/m2)  given  only  for 
1  day  before  the  transplantation  (day  minus  6)  +  etoposide 
(VP-16—250 mg/m2) given for 3 consecutive days two times a 
day, starting 6 days before the transplantation (days minus 6 to 
minus 4) or BEAM: carmustine (BCNU—300 mg/m2) given only 
for 1 day before the transplantation (day minus 7) + etoposide 
(VP-16—200  mg/m2)  given  for  4  consecutive  days  two  times 
a day, starting 6 days before the transplantation (days minus 6 
to minus 3) + cytarabine (100 mg/m2) given for 4 consecutive 
days two times a day, starting 6 days before the transplantation 
(days minus 6 to minus 3) + melphalan (140 mg/m2) given only 
for 1 day before the transplantation (day minus 6) for Hodgkin 
and  non-Hodgnkin  lymphomas  in  PBSCT.  FluCy:  fludarabine   
(30  mg/m2)  +  cyclophosphamide  (300  mg/m2),  both  given  for 
3  consecutive  days,  starting  4  days  before  the  transplantation   
(days  minus  4  to  minus  2)  for  Hodgkin  and  non-Hodgnkin 
lymphomas  in  BMT.  BuCy120:  busulfan  (1  mg/kg),  given  for 
4 consecutive days, four times a day, starting 8 days before the 
Table 3  Influence of age on engraftment
  <20 years  20–29 years  30–39 years  40–49 years  50–59 years  ≥60 years 
  (n = 10)  (n = 10)  (n = 10)  (n = 15)  (n = 16)  (n = 04)
No engraftment  01      01  01 
  (01 PBSCT)      (01 BMT)  (01 BMT)
Engraftment  09  10  10  14  15  04
  (07 BMT,   (07 BMT,   (08 BMT,   (08 BMT,   (06 BMT,  (02 BMT,  
  02 PBSCT)  03 PBSCT)  02 PBSCT)  06 PBSCT)  09 PBSCT)  02 PBSCT)
Neutrophil engraftment  19.00  18.50  17.00  15.00  11.00  11.50
(day)  (16.00/29.00)a  (11.00/24.00)  (13.00/19.00)  (11.00/21.00)  (10.00/18.00)  (10.00/18.00)
Platelet engraftment  21.00  22.00  15.00  18.50  13.00  15.00
(day)  (17.00/25.00)  (13.00/25.00)a  (13.00/21.00)  (11.00/23.00)  (10.00/21.00)  (11.00/20.00)
OS (<6 months)  08/10 (80.00%)  09/10 (90.00%)  10/10 (100%)  14/15 (93.33%)  14/16 (87.50%)  4/4 (100%)
OS (6–12 months)  08/10 (80.00%)  07/10 (70.00%)  10/10 (100%)  10/15 (66.67%)  13/16 (81.25%)  4/4 (100%)
OS: overall survival; Neutrophil and platelet engraftment were expressed as median (lower/upper quartile). aSignificantly different from 50–59 years old.
Table 4  Influence of disease type on engraftment
  MM  Lymphoma  Leukemia  SMD  AA 
  (n = 12)  (n = 21)  (n = 16)  (n = 08)  (n = 08)
No engraftment    01  01    01
Engraftment  12  20  15  08  07
Neutrophil engraftment (day)  11.00  10.00  18.00  20.50  22.00 
  (10.00/11.50)  (09.00/15.50)  (16.00/20.00)ab  (18.50/25.50)ab  (18.00/29.00)ab
Platelet engraftment (day)  11.00  13.00  21.00  23.00  24.00 
  (10.00/13.00)  (10.50/16.00)  (17.00/25.00)ab  (21.00/26.50)ab  (20.00/29.00)ab
OS (<6 months)  12/12 (100%)  19/21 (90.48%)  14/16 (87.50%)  08/08 (100%)  07/08 (87.50%)
OS (6–12 months)  12/12 (100%)  17/21 (80.95%)   12/16 (75.00%)  05/08 (62.50%)*  07/08 (87.50%)
MM, multiple myeloma; SMD, syndrome myelodysplastic; AA, aplastic anemia; OS, overall survival; Neutrophil and platelet engraftment were expressed as median (lower/upper quartile). aSignificantly different 
from MM. bSignificantly different from Lymphoma. *OS significantly different from MM.
Table 5    Influence of transplantation type and graft 
source on engraftment
  Allogeneic BMT  Autologous PBSCT 
  (n = 40)  (n = 25)
No engraftment  02  01
Engraftment  38  24
Neutrophil engraftment (day)  19.00  10.00 
  (16.00/23.00)  (09.00/11.00)a
Platelet engraftment (day)  21.00  11.00 
  (18.00/25.00)  (10.00/13.00)a
OS (<6 months)  34/40 (85.00%)  24/25 (96.00%)
OS (6–12 months)  31/40 (77.50%)  22/25 (88.00%)
BMT, bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; OS, overall 
survival; Neutrophil and platelet engraftment were expressed as median (lower/upper quartile). aSig-
nificantly different between Allogeneic BMT and Autologous PBSCT.Autologous and allogeneic hematopoietic stem cell transplantation
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chronic myeloid leukemia and syndrome myelodysplastic in BMT. 
BuCy200: busulfan (1 mg/kg), given for 3 consecutive days four 
times a day, starting 9 days before the transplantation (days minus 9 
to minus 7) + cyclophosphamide (50 mg/m2), given for 4 consecu-
tive days, starting 6 days before the transplantation (days minus 
6 to minus 3) or Cy200: cyclophosphamide (40 mg/m2), given 
for 5 consecutive days, starting 5 days before the transplantation   
(days minus 5 to minus 1) for aplastic anemia in BMT. CyTBI: 
cyclophosphamide  (60  mg/m2),  given  for  2  consecutive  days, 
starting 7 days before the transplantation (days minus 7 to minus 
6) + total body irradiation, made for 4 consecutive days, starting 
4 days before the transplantation (days minus 4 to minus 2, three 
times on day and day minus 1, two times on day) for acute and 
chronic lymphoid leukemia in BMT. All patients had 2 rest days 
(without chemotherapy) before the transplantation (days minus 2 
and minus 1), except FluCy and CyTBI CR patients, that had only 
one rest day (day minus 1 and minus 5, respectively).
Engraftment. Neutrophil engraftment was defined as the first 
of three consecutive days post-transplant with neutrophil counts 
>500/mm3,  while  platelet  engraftment  was  defined  as  first  of 
three consecutive days post-transplant untransfused platelets, with 
counts >20,000/mm3.
Statistical analysis. Sex, age, disease, graft source and condi-
tioning  regimens  were  examined  in  terms  of  their  effect  on 
neutrophil and platelet engraftment.
Variables were compared using Kruskal-Wallis ANOVA followed 
by Mann-Whitney U test. Overall survival was estimated using the 
Fisher test.
p-value <0.05 was considered statistically significant.
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Table 6  Influence of conditioning regimen on engraftment
  M-200  CBV  BEAM  FluCy  BuCy120  BuCy200  Cy200  CyTBI 
  (n = 12)  (n = 13)  (n = 05)  (n = 04)  (n = 19)  (n = 03)  (n = 05)  (n = 04)
No engraftment    01       01  01  
engraftment  12  12  05  04  18  02  05  04
Neutrophil  11.00  09.00  19.00  12.50  19.00  23.50  19.00  20.00 
engraftment  (10.00/11.50)d  (09.00/10.50)ad  (10.00/24.00)ab  (11.50/16.00)b  (18.00/23.00)cab  (22.00/25.00)cab  (18.00/  (17.50/ 
(day)              29.00)  21.00)cab
Platelet  11.00  11.50  20.00  15.50  22.00  25.00  22.00  20.00 
engraftment  (10.00/13.00)d  (10.00/13.00)ad  (11.00/24.00)ab  (13.50/17.50)b  (21.00/25.00)cab  (24.00/26.00)cab  (20.00/  (18.00/ 
(day)              29.00)  22.00)cab
OS   12/12 (100%)  12/13 (92.30%)  04/05 (80.00%)  04/04 (100%)  18/19 (94.74%)  02/03 (66.67%)  04/05  03/04 
(<6 months)              (80%)  (75.00%)
OS  12/12 (100%)  10/13 (76.92%)  04/05 (80.00%)  04/04 (100%)  15/19 (78.95%)  01/03 (33.33%)*  04/05  02/04 
(6–12 months)              (80%)  (50.00%)*
M-200, melphalan 200 mg; CBV, cyclophosphamide + BCNU + etoposide; BEAM, BCNU + etoposide + arabynoside + melphalan; FluCy, fludarabine + cyclophosphamide; BuCy120, busulfan + cyclophos-
phamide 120 mg; BuCy200, busulfan + cyclophosphamide 200 mg; Cy200, cyclophosphamide 200 mg; CyTBI, cyclophosphamide + total body irradiation. Data were expressed as median (lower/upper quartile). 
aSignificantly different from M-200. bSignificantly different from CBV. cSignificantly different from FluCy. dSignificantly different from Cy200. *OS significantly different from M-200.www.landesbioscience.com Oxidative Medicine and Cellular Longevity 87
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